Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects.

@article{citeulike:3198989, abstract = {Three independent, phase 1 clinical trials were conducted in Australia and in USA to assess the safety and immunogenicity of sanofi pasteur dengue vaccine candidates. In this context, Dengue 1-4 and Yellow Fever 17D-204 (YF 17D)-specific CD4 and CD8 cellular responses induced by tetravalent chimeric dengue vaccines (CYD) were analyzed in flavivirus-naive or flavivirus-immune patients. Tetravalent CYD vaccine did not trigger detectable changes in serum pro-inflammatory cytokines, whatever the vaccinees immune status, while inducing significant YF 17D NS3-specific CD8 responses and dengue serotype-specific T helper responses. These responses were dominated by serotype 4 in naive individuals, but a booster vaccination (dose \#2) performed 4 months following dose \#1 broadened serotype-specific responses. A similar, broader response was seen after primary tetravalent immunization in subjects with pre-existing dengue 1 or 2 immunity caused by prior monovalent live-attenuated dengue vaccination. In all three trials, the profile of induced response was similar, whatever the subjects' immune status, i.e. an absence of Th2 response, and an IFN-gamma/TNF-alpha ratio dominated by IFN-gamma, for both CD4 and CD8 responses. Our results also showed an absence of cross-reactivity between YF 17D or Dengue NS3-specific CD8 responses, and allowed the identification of 3 new CD8 epitopes in the YF 17D NS3 antigen. These data are consistent with the previously demonstrated excellent safety of these dengue vaccines in flavivirus-naive and primed individuals.}, address = {Research Department, Sanofi pasteur, Marcy l'Etoile, France.}, author = {Guy, Bruno and Nougarede, Nolwenn and Begue, Sarah and Sanchez, Violette and Souag, Nadia and Carre, Murielle and Chambonneau, Laurent and Morrisson, Dennis N N. and Shaw, David and Qiao, Ming and Dumas, Rafaele and Lang, Jean and Forrat, Remi }, citeulike-article-id = {3198989}, doi = {http://dx.doi.org/10.1016/j.vaccine.2008.08.019}, issn = {0264-410X}, journal = {Vaccine}, month = {August}, posted-at = {2008-09-06 07:43:21}, priority = {2}, title = {Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects.}, url = {http://dx.doi.org/10.1016/j.vaccine.2008.08.019}, year = {2008} }

TY - JOUR ID - citeulike:3198989 L3 - citeulike-article-id:3198989 N2 - Three independent, phase 1 clinical trials were conducted in Australia and in USA to assess the safety and immunogenicity of sanofi pasteur dengue vaccine candidates. In this context, Dengue 1-4 and Yellow Fever 17D-204 (YF 17D)-specific CD4 and CD8 cellular responses induced by tetravalent chimeric dengue vaccines (CYD) were analyzed in flavivirus-naive or flavivirus-immune patients. Tetravalent CYD vaccine did not trigger detectable changes in serum pro-inflammatory cytokines, whatever the vaccinees immune status, while inducing significant YF 17D NS3-specific CD8 responses and dengue serotype-specific T helper responses. These responses were dominated by serotype 4 in naive individuals, but a booster vaccination (dose #2) performed 4 months following dose #1 broadened serotype-specific responses. A similar, broader response was seen after primary tetravalent immunization in subjects with pre-existing dengue 1 or 2 immunity caused by prior monovalent live-attenuated dengue vaccination. In all three trials, the profile of induced response was similar, whatever the subjects' immune status, i.e. an absence of Th2 response, and an IFN-gamma/TNF-alpha ratio dominated by IFN-gamma, for both CD4 and CD8 responses. Our results also showed an absence of cross-reactivity between YF 17D or Dengue NS3-specific CD8 responses, and allowed the identification of 3 new CD8 epitopes in the YF 17D NS3 antigen. These data are consistent with the previously demonstrated excellent safety of these dengue vaccines in flavivirus-naive and primed individuals. JF - Vaccine SN - 0264-410X AD - Research Department, Sanofi pasteur, Marcy l'Etoile, France. TI - Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. AU - Guy, Bruno AU - Nougarede, Nolwenn AU - Begue, Sarah AU - Sanchez, Violette AU - Souag, Nadia AU - Carre, Murielle AU - Chambonneau, Laurent AU - Morrisson, Dennis N AU - Shaw, David AU - Qiao, Ming AU - Dumas, Rafaele AU - Lang, Jean AU - Forrat, Remi PY - 2008/08/29/ UR - http://dx.doi.org/10.1016/j.vaccine.2008.08.019 ER -